Calamos Advisors
KRTX

Calamos Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Calamos Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,381
Closed -$950K – 1018
2023
Q2 		$950K Buy
4,381
+2,929
+202% +$628K ﹤0.01% 713
2023
Q1 		$264K Buy
+1,452
New +$278K ﹤0.01% 877

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Calamos Advisors's KRTX Position: Q3 2023 in Review

Calamos Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 4,381 shares — an estimated $950K sold.

Calamos Advisors first reported a position in KRTX in Q1 2023 and held it in 2 quarters. The position peaked at $950K in Q2 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Calamos Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Calamos Advisors sold 4,381 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $950K.
  • Calamos Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Calamos Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $950K in Q2 2023.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Calamos Advisors's 13F filing for Q3 2023, filed 26 Oct 2023.